Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company headquartered in New York, NY, dedicated to transforming healthcare through pioneering science. The company's mission is to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated by developing meaningful genetic medicines that address the underlying genetic causes of these devastating conditions.

Lexeo Therapeutics focuses on advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates. Key product candidates include LX2006, which is in Phase 1/2 clinical trials for Friedreich's ataxia cardiomyopathy and has received multiple FDA designations including Breakthrough Therapy and Orphan Drug. LX2020 is another lead candidate in Phase 1/2 trials for arrhythmogenic cardiomyopathy (PKP2-ACM), also holding Orphan Drug and Fast Track designations. Additionally, the company is developing LX1001 for APOE4 homozygous patients with Alzheimer's disease, and other programs for various inherited cardiac muscle disorders.

Lexeo Therapeutics completed its Initial Public Offering (IPO) in November 2023, with shares trading on The Nasdaq Global Market under the symbol "LXEO". Recent activities include reporting Q1 2026 financial results and participating in healthcare conferences in May 2026. In March 2026, the company reported its Q4 and full-year 2025 financial results, indicating a cash position sufficient to fund operations into 2028, and presented positive interim clinical data for LX2020. In January 2026, Lexeo announced key leadership appointments and provided an update on a strategic partnership for novel cardiac RNA therapeutics, following a June 2025 agreement to develop non-viral RNA-based therapies for genetic cardiac diseases through a new spinout entity.